175 results on '"Huang, Hui"'
Search Results
2. Developing CD70-Targeted CAR-T Cells for the Treatment of Hematological and Solid Malignancies
3. Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial
4. Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies
5. Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma
6. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma
7. Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma
8. Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex
9. Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study
10. Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial
11. Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)
12. Thalidomide Maintenance in Patients with Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation: Single-Center Experience
13. P-Gemox Regimen(Pegaspargase, Gemcitabine, oxaliplatin) for Extranodal Natural Killer Cell Lymphoma: 10 Years' Real-World Clinical Experience from China
14. Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy
15. RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia
16. Open-Label Study of Bendamustine Hydrochloride in Chinese Patients with Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
17. A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia
18. Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US
19. The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation
20. Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients
21. Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).
22. Comparative Efficacy Among 3rd Line Post-Imatinib Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of Dasatinib or Nilotinib Tyrosine Kinase Inhibitors
23. Real-World Prescribing Patterns with Ponatinib Among New and Ongoing US Patients
24. Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison
25. Safety and Clinical Activity Of Crizotinib In Patients With ALK-Rearranged Hematologic Malignancies
26. The Serum Spectrum Of Cytokines In Patients With NK/T-Cell Lymphoma and Its Cilincial Significance In Survival
27. Efficacy and Safety Of Pegaspargase With Gemcitabine and Oxaliplatin In Patients With Treatment-naïve, Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Single-Centre Experience
28. The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma
29. IL-6 Promotes Cell Proliferation and Antiapoptosis Through Activation Of The JAK/STAT3 Pathway In Patients With NK/T - Cell Lymphoma and Correlates With Poor Treatmemt Outcome
30. Src Kinase Can Activate RUNX1 Activity Via Phosphorylation Of C-Terminal Tyrosines and Activated RUNX1 Stimulates Granulopoiesis
31. Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML)
32. The Activation Of M2 Polarized Tumor-Associated Macrophages In The Microenvironment Of NK/T-Cell Lymphoma and The Characteristics Of Cytokine Spectrum
33. Novel Combination Of Lenalidomide-Rituximab Provides An Effective Bridge To Stem Cell Transplantation In Relapsed and/Or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphomas: A Single Center Experience
34. Comparative Efficacy Among Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients After Failure Of 2nd Generation Tyrosine Kinase Inhibitors (2G TKIs)
35. Essential Role of the Transcription Factor ZBP-89 in Lymphopoiesis
36. Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal-Doxorubicin (GVD) As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma
37. Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study
38. Role of ZBP-89 in human globin gene regulation and erythroid differentiation
39. Role of the Krüppel-Type Zinc Finger Transcription Factor ZBP-89 In Human Globin Gene Regulation and Erythroid Development
40. Role of Polycomb Repressive Complex 1 (PRC1) In Runx1 Mediated Gene Regulation
41. The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States
42. Tyrosine Phosphorylation of Runx1 In Megakaryocytes by Src Family Kinases
43. The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.
44. Multiple Myeloma: Patient out-of-Pocket Costs and Health Care Utilization.
45. An Economic Evaluation of Bortezomib-Based Induction Therapy in Double Transplant Protocols for Newly Diagnosed Multiple Myeloma Patients
46. Transcriptional Regulation of Thrombopoiesis.
47. Differentiation-Dependent Interactions Between Runx-1 and Fli-1 during Megakaryocyte Development
48. A Budget Impact Model Comparing Resource Utilization of Four Approved Therapies for Multiple Myeloma (MM) in the US.
49. Engraftment of MDR1and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy
50. Chidamide ,Oral Subtype-Selective Histone Deacetylase Inhibitor (HDACI) Monotherapy Was Effective on the Patients with Relapsed or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.